论文部分内容阅读
1979年Masson首先发现反复肌注丙种球蛋白的慢性血小板减少症患者,其血小板数可获短期增高。以后Barandum等观察到免疫抑制的患者,在用大剂量免疫球蛋白注射治疗严重病毒感染的同时,原来缺乏的血小板显著增高。由此引起血液工作者的极大兴趣,并广泛试用于免疫性血液病如特发性血小板减少性紫癜(idiopathicthrombocytopenicpurpura,ITP)、免疫性白细胞减少症和慢性淋巴细胞白血病等的治疗以及骨髓移植等患者感染的预防。给药的途径也从肌注改为静脉滴注,因为肌注有以下缺点:①高浓度免疫球蛋白肌注,局部疼痛明显;②应用剂量受到限制;③部分抗体可能
In 1979, Masson first found that patients with chronic thrombocytopenia who had repeated intramuscular gamma globulin therapy had a short-term increase in platelet count. After Barandum and other patients observed immunosuppression in the treatment of severe viral infections with high-dose immunoglobulin at the same time, the original lack of platelets increased significantly. This has caused great interest among blood workers and has been extensively tested for the treatment of immune blood diseases such as idiopathic thrombocytopenic purpura (ITP), immune leucopenia and chronic lymphocytic leukemia, and bone marrow transplantation Prevention of patient infection. The route of administration is also changed from intramuscular injection to intravenous infusion, because intramuscular injection has the following disadvantages: (1) intramuscular injection of high concentration of immunoglobulin, local pain was obvious; (2) application dose was limited; (3) partial antibody may